Merrimack Pharma-Ipsen’s Cancer Drug Fails In Overall Survival Measure
Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK) partner announced that Ipsen SA (OTC:IPSEY) reported a primary analysis of the results of the…
Ipsen – Exelixis’ Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
The European Commission (EC) has approved Ipsen SA’s (OTC:IPSEY) Cabometyx (cabozantinib) as monotherapy in differentiated thyroid carcinoma (DTC) setting. The approval…
EMA’s Scientific Committee Backs Expanded Use Of Exelixis, Ipsen’s Cabometyx In Thyroid Cancer
Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have
Ipsen’s Sohonos Scores Canadian Approval For Rare Connective Tissue Disease
Health Canada has approved Ipsen SA’s (OTC:IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for…
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
Ipsen SA (OTC: IPSEY) has
Ipsen Stock Declines After Pulling Rare Disease Application
Ipsen (OTC:IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two…
Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
Ipsen SA (OTC:IPSEY) and Exicure Inc (NASDAQ:XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments…
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Exelixis Inc (NASDAQ:EXEL) and Ipsen (OTC:IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (Cabometyx) in combination with Roche…